Premium
Serum dopamine‐β‐hydroxylase levels in Down's syndrome
Author(s) -
Coleman Mary,
Campbell MaCda,
Freedman Lewis S.,
Roffman Mark,
Ebstein Richard P.,
Goldstein Menek
Publication year - 1974
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/j.1399-0004.1974.tb01699.x
Subject(s) - medicine , endocrinology , down syndrome , mongoloid , population , psychiatry , environmental health
Serum dopamine‐β‐hydroxylase (DBH) and serum immunoreactive (IR) DBH levels were measured in patients with Down's syndrome. Serum DBH activity was markedly reduced in Down's syndrome patients as compared with age matched, normal controls or non‐mongoloid, disturbed children. Serum IR‐DBH levels were also markedly reduced in Down's syndrome. The possible factors responsible for the observed reduction in serum DBH levels (active and inactive enzyme levels) in Down's syndrome were investigated.